Oramed Pharmaceuticals Aktie
WKN DE: A1CTNU / ISIN: US68403P2039
12.01.2023 16:22:03
|
Oramed Pharma Plunges After Its Diabetes Drug Failed In Late-stage Study
(RTTNews) - Shares of Oramed Pharmaceuticals Inc. (ORMP) are falling more than 75% Thursday morning after the company's investigational drug ORMD-0801 for the treatment of Type 2 Diabetes failed in late-stage study.
Phase 3 study comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes did not meet its primary goal of glycemic control improvement, the company said.
ORMP, currently at $2.60, touched a new low of $2.32 this morning.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Oramed Pharmaceuticals Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Oramed Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Oramed Pharmaceuticals Inc | 2,02 | -0,25% |
|